It will list 5 million shares at between $14 and $16 each to give an initial market capitalisation of about $215m, were it to price in the middle of its range.
Regado Biosciences, a US-based thrombosis treatment company backed by local drugs group Baxter’s corporate venturing unit, plans to raise at least $70m in its flotation on the Nasdaq stock exchange.
It will list 5 million shares at between $14 and $16 each to give an initial market capitalisation of about $215m, were it to price in the middle of its range.
Investment banks Cowan and BMO Capital Markets are advising the initial public offering (IPO), with legal counsel from Lowenstein…
